Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...

The US Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc ...

在中国，ocrelizumab（奥瑞利珠单抗，静脉注射剂型）的上市申请已经于2023年7月获得NMPA受理。该静脉注射剂型产品同样每年只需输注两次，有望显著改善多发性硬化患者的依从性。

The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...

The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first ...

Ocrevus Zunovo can be administrated by providers twice a year with a 10-minute subcutaneous injection. Ocrevus Zunovo will be ...

US FDA approves Roche’s Ocrevus Zunovo to treat relapsing multiple sclerosis and PPMS: Basel Tuesday, September 17, 2024, 10:00 Hrs [IST] Roche announced that the United States ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...

The Food and Drug Administration (FDA) has approved Tecentriq Hybreza ™ (atezolizumab and hyaluronidase-tqjs) for subcutaneous (SC) injection, for all the approved adult indications of intravenous ...

Basel: Roche announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO ...

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) ...

Swiss drug major Roche (RHHBY) announced Monday that the United States Food and Drug Administration has approved OCREVUS ZUNOVO ...